Q1FY22 Earnings Presentation

8 Strides Other regulated market reports a weak quarter, business to bounce back starting Q2FY22 Financial Performance (*/$M) QUARTER ON QUARTER 2,722 $37 €2,232 $30 DQ4FY21 DQ1FY22 YEAR ON YEAR 2,606 $35 * 2,232 $30 OQ1 FY21 0Q1FY22 >>> - 18% QoQ >>> - 14% YoY Business Updates Revenues from other regulated markets for Q1FY22 stood at *2,232m ($30m), down 14% YoY, representing 32% of consolidated revenues for Q1FY22 Performance during the quarter was impacted due to significant decline in prescription generations for Rx and OTC products owing to 2nd Covid- 19 wave and lockdown in UK / other parts of Europe Witnessed supply delays for partnered business owing to significant disruptions at our manufacturing sites in India with surge in Covid-19 cases during the quarter Continued R&D investments for portfolio building, focus on consistent product launches Near Term Outlook Healthy order book across markets to drive a bounce back starting Q2FY22 Business outlook continues to be robust, the business will benefit from a enhanced market footprint and a large product basket available for commercialization 6 YoY comparison in INR reported

View entire presentation